Capital Advisors Ltd’s TScan Therapeutics TCRX Stock Holding History

Capital Advisors Ltd’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2	Closed	–	–	1573
2024 Q3	$0	Buy	+2	New	+$12	﹤0.01%	1602

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Capital Advisors Ltd's TCRX Position: Q4 2024 in Review

Capital Advisors Ltd sold out of TScan Therapeutics (TCRX) in Q4 2024, closing a stake of 2 shares.

Capital Advisors Ltd first reported a position in TCRX in Q3 2024 and held it in 1 quarter. The position peaked at $0 in Q3 2024. 89 funds tracked by Wall St. Rank hold TCRX as of Q4 2024.

Capital Advisors Ltd reported no remaining TScan Therapeutics position as of Q4 2024 after selling out during the quarter.
Capital Advisors Ltd sold 2 TScan Therapeutics shares in Q4 2024.
Capital Advisors Ltd first reported a position in TScan Therapeutics in Q3 2024 and held it in 1 quarter.
Capital Advisors Ltd's TScan Therapeutics position peaked at $0 in Q3 2024.
89 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2024.

Based on Capital Advisors Ltd's 13F filing for Q4 2024, filed 4 Feb 2025.